Dedifferentiated thyroid cancer: a therapeutic challenge

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Human papillary dedifferentiated thyroid cancer (HPDTC) poses significant therapeutic challenges.
• Emerging targeted therapies (RET, BRAF) and PPARg agonists show promise for HPDTC treatment.
• Current novel therapies lack significant clinical impact on patient survival.

Purpose of the Study:

• To explore novel therapeutic strategies for HPDTC.
• To investigate the potential of patient-derived primary cells for predicting treatment response.
• To enhance patient selection for targeted and redifferentiating therapies.

Main Methods:

• Development of primary cell cultures from fine needle aspiration samples of HPDTC patients.
• Implementation of chemosensitivity assays on primary tumoral cells.
• Evaluation of targeted therapies (RET, BRAF) and PPARg agonists in preclinical models.

Main Results:

• Primary cell models derived from HPDTC enable the study of individual tumor biology.
• Chemosensitivity testing in primary cells can identify patients likely to respond to specific drugs.
• This approach may prevent the administration of ineffective treatments, optimizing therapeutic strategies.

Conclusions:

• Patient-derived primary cells are crucial for personalized medicine in HPDTC.
• Chemosensitivity testing holds potential for improving therapeutic efficacy and patient survival in HPDTC.
• Future research should focus on integrating these models into clinical decision-making for HPDTC management.